1. The Association between 25-Hydroxyvitamin D and Hemoglobin A1c Levels in Patients with Type 2 Diabetes and Stage 1-5 Chronic Kidney Disease.

    International Journal of Endocrinology 2014:142468 (2014) PMID 25250050 PMCID PMC4163314

    Aim. To examine the relationship between plasma 25-hydroxyvitamin D (25(OH)D) levels and blood hemoglobin A1c (HbA1c) levels in diabetic patients at various stages of chronic kidney disease (CKD). Methods. We screened for data collected between 2003 and 2012. The correlation between 25(OH)D and ...
  2. The Association between 25-Hydroxyvitamin D and Hemoglobin A1c Levels in Patients with Type 2 Diabetes and Stage 1-5 Chronic Kidney Disease.

    International Journal of Endocrinology 2014:142468 (2014) PMID 25250050 PMCID PMC4163314

    Aim. To examine the relationship between plasma 25-hydroxyvitamin D (25(OH)D) levels and blood hemoglobin A1c (HbA1c) levels in diabetic patients at various stages of chronic kidney disease (CKD). Methods. We screened for data collected between 2003 and 2012. The correlation between 25(OH)D and ...
  3. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

    Drugs in R&D 13(3):165 (2013) PMID 24000048 PMCID PMC3784056

    Hyperphosphatemia in chronic kidney disease (CKD) has been associated with elevated cardiovascular morbidity and mortality. Serum phosphate control remains a cornerstone of the clinical management of patients with CKD, in order to both attenuate the progression of secondary hyperparathyroidism o...
  4. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

    Drugs in R&D 13(3):165 (2013) PMID 24000048 PMCID PMC3784056

    Hyperphosphatemia in chronic kidney disease (CKD) has been associated with elevated cardiovascular morbidity and mortality. Serum phosphate control remains a cornerstone of the clinical management of patients with CKD, in order to both attenuate the progression of secondary hyperparathyroidism o...
  5. Association between angiotensin receptor blockers and better cognitive outcome: urgent need for a randomized trial.

    JAMA Neurology 70(3):413 (2013) PMID 23478839

  6. Association between angiotensin receptor blockers and better cognitive outcome: urgent need for a randomized trial.

    JAMA Neurology 70(3):413 (2013) PMID 23478839

  7. Serious spontaneous epistaxis and hypertension in hospitalized patients.

    Archiv für Ohren- Nasen- und Kehlkopfheilkunde 268(12):1749 (2011) PMID 21656167

    The aim of the study was to evaluate the role of hypertension in patients hospitalized for serious spontaneous epistaxis. This 6-year retrospective study was based on 219 patients hospitalized in a University Hospital ENT and Head and Neck surgery department for serious spontaneous epistaxis. Th...
  8. Serious spontaneous epistaxis and hypertension in hospitalized patients.

    Archiv für Ohren- Nasen- und Kehlkopfheilkunde 268(12):1749 (2011) PMID 21656167

    The aim of the study was to evaluate the role of hypertension in patients hospitalized for serious spontaneous epistaxis. This 6-year retrospective study was based on 219 patients hospitalized in a University Hospital ENT and Head and Neck surgery department for serious spontaneous epistaxis. Th...
  9. Rationale and trial design to validate an optimal dual antihypertensive treatment for prevention of dementia in very elderly patients

    Alzheimer's & Dementia 6(4):S178 (2010)

  10. Rationale and trial design to validate an optimal dual antihypertensive treatment for prevention of dementia in very elderly patients

    Alzheimer's & Dementia 6(4):S178 (2010)

  11. Are angiotensin AT1 receptor blockers better at preventing dementia than angiotensin converting enzyme inhibitors? An update

    Alzheimer's & Dementia 6(4):S178 (2010)

  12. Pathophysiological mechanisms potentially implied in the better prevention of dementia with angiotensin AT1 receptor blockers than with angiotensin converting enzyme inhibitors

    Alzheimer's & Dementia 6(4):S222 (2010)

  13. Are angiotensin AT1 receptor blockers better at preventing dementia than angiotensin converting enzyme inhibitors? An update

    Alzheimer's & Dementia 6(4):S178 (2010)

  14. Pathophysiological mechanisms potentially implied in the better prevention of dementia with angiotensin AT1 receptor blockers than with angiotensin converting enzyme inhibitors

    Alzheimer's & Dementia 6(4):S222 (2010)

  15. Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

    Expert Review of Neurotherapeutics 9(9):1289 (2009) PMID 19769445

    First, an update of the vascular systemic and tissue renin-angiotensin-aldosterone system is provided to explain how it is regulated at the systemic and tissue levels, and how many angiotensin peptides and receptors can be modulated by the various antihypertensive drugs. Second, experimental dat...
  16. Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

    Expert Review of Neurotherapeutics 9(9):1289 (2009) PMID 19769445

    First, an update of the vascular systemic and tissue renin-angiotensin-aldosterone system is provided to explain how it is regulated at the systemic and tissue levels, and how many angiotensin peptides and receptors can be modulated by the various antihypertensive drugs. Second, experimental dat...
  17. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

    Expert Review of Neurotherapeutics 9(9):1413 (2009) PMID 19769454

    Our review of cohort studies and clinical trials evaluating antihypertensive drugs in the prevention of cognition decline and all dementia in patients with hypertension indicates that two antihypertensive drug classes have greater protective effects, independent of blood pressure decrease: dihyd...
  18. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

    Expert Review of Neurotherapeutics 9(9):1413 (2009) PMID 19769454

    Our review of cohort studies and clinical trials evaluating antihypertensive drugs in the prevention of cognition decline and all dementia in patients with hypertension indicates that two antihypertensive drug classes have greater protective effects, independent of blood pressure decrease: dihyd...
  19. Vitamin D affects survival independently of vascular calcification in chronic kidney disease.

    Clinical Journal of the American Society of Nep... 4(6):1128 (2009) PMID 19443628 PMCID PMC2689889

    Cardiovascular disease is the main cause of mortality in chronic kidney disease (CKD) patients. Vitamin D might have beneficial effects on vascular health. The aim of this study was to determine the prevalence of vitamin D deficiency (25-hydroxyvitamin D [25D]
  20. Vitamin D affects survival independently of vascular calcification in chronic kidney disease.

    Clinical Journal of the American Society of Nep... 4(6):1128 (2009) PMID 19443628 PMCID PMC2689889

    Cardiovascular disease is the main cause of mortality in chronic kidney disease (CKD) patients. Vitamin D might have beneficial effects on vascular health. The aim of this study was to determine the prevalence of vitamin D deficiency (25-hydroxyvitamin D [25D]